Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06910657 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

IDOV-Immune for Advanced Solid Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 1 of 5 sitesv12
  2. Study sites: 6 to 5v11
  3. Site details revised at 1 of 6 sitesv10
  4. Site details revised at 1 of 6 sitesv9
  5. Primary endpoints revised (4)
    • Secondary endpoints: 9 to 8
    v8
Show 6 earlier versionsHide 6 earlier versions
  1. Site details revised at 1 of 6 sitesv7
  2. Site contacts updated at 1 of 6 sitesv6
  3. Site contacts updated at 1 of 6 sitesv5
  4. Site contacts updated at 1 of 6 sitesv4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 5 to 6
    • Start date changed from estimate of Jun 1, 2025 to Aug 25, 2025
    v3
  6. Study title shortened, about 12 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
ViroMissile, Inc.
1 trial monitored
See all monitored trials
Breast Cancer
5,418 trials monitored
See 296 trials at risk
Lung Cancer
4,790 trials monitored
See 263 trials at risk
Colorectal Cancer
3,394 trials monitored
See 159 trials at risk
and 12 more diseases
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor. The purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely given. Researchers will also study how the drug behaves in the body, how the immune system responds to it, and whether it shows any signs of shrinking tumors. Participants will receive a single intravenous (IV) infusion of IDOV-Immune and will be closely monitored for side effects and any changes in their cancer. This study is being conducted at multiple sites in the United States and Australia.
Trial Details
NCT Number NCT06910657
Lead Sponsor ViroMissile, Inc.
Conditions
(from sponsor)		 Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma +8 more
Related terms Adrenal Gland Neoplasms, Breast Neoplasms, Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Colorectal Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Vaccinia
Enrollment 78 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov